Verified factor-similar pair

CSD vs IJJ

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
85
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • IJJ has the higher backtested relative Sharpe (1.083 vs 0.927).
  • IJJ has the lower published fee (0.18% vs 0.67%).
  • IJJ is cheaper on dividend valuation (109 vs 420, where 100 is each fund's historical median).
  • IJJ has the stronger regression fit (adjusted R-squared 0.946 vs 0.833).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

CSD

Invesco S&P Spin-Off ETF
SMB
Adj. R2
0.833
Rel. Sharpe
0.927
Mkt beta
1.13
AUM
US$114M
MER
0.67%
Valuation
420

IJJ

iShares S&P Mid-Cap 400 Value ETF
SMB
Adj. R2
0.946
Rel. Sharpe
1.083
Mkt beta
1.00
AUM
US$8.3B
MER
0.18%
Valuation
109

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
CSD
+0.50
|t|
+6.6
IJJ
+0.54
|t|
+18.6
diff -0.04
HML
CSD
+0.15
|t|
+2.0
IJJ
+0.26
|t|
+8.7
diff -0.11
RMW
CSD
+0.06
|t|
+0.7
IJJ
+0.22
|t|
+6.7
diff -0.15
CMA
CSD
+0.03
|t|
+0.2
IJJ
+0.12
|t|
+2.7
diff -0.09
UMD
CSD
-0.02
|t|
-0.4
IJJ
-0.04
|t|
-2.3
diff +0.02

Why This Pair Matches

Exposure level
84
Exposure shape
98
Mkt beta diff
0.13
Rel. Sharpe diff
0.156

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

CSD fund page IJJ fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.